NCT05178576 2022-11-04A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant ChemotherapyNSABP Foundation IncPhase 2 Withdrawn